7. Active malignancy besides NSCLC within 3 years prior to screening. Exceptions: adequately treated malignancies not likely to require therapy (e.g. completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma). Subjects must be in complete remission from prior malignancy in order to be eligible to enter the study.